Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurr...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine Jg. 384; H. 2; S. 129 - 139 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Massachusetts Medical Society
14.01.2021
|
| Schlagworte: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin. |
|---|---|
| AbstractList | BackgroundThe efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.MethodsWe conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding.ResultsOf 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P=0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo.ConclusionsIn patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.) The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding. Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo. In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.). In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin. The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.BACKGROUNDThe efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding.METHODSWe conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding.Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo.RESULTSOf 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo.In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).CONCLUSIONSIn patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.). |
| Author | Riddle, Matthew C Inzucchi, Silvio E Cannon, Christopher P Cherney, David Z.I Bhatt, Deepak L Szarek, Michael Bailey, Clifford J Lopes, Renato D Díaz, Rafael Ray, Kausik K Leiter, Lawrence A Scirica, Benjamin M Udell, Jacob A Steg, P. Gabriel Lewis, Julia B McGuire, Darren K Lapuerta, Pablo Kosiborod, Mikhail N Pitt, Bertram Dwyer, Jamie P |
| Author_xml | – sequence: 1 givenname: Deepak L surname: Bhatt fullname: Bhatt, Deepak L organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 2 givenname: Michael surname: Szarek fullname: Szarek, Michael organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 3 givenname: Bertram surname: Pitt fullname: Pitt, Bertram organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 4 givenname: Christopher P surname: Cannon fullname: Cannon, Christopher P organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 5 givenname: Lawrence A surname: Leiter fullname: Leiter, Lawrence A organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 6 givenname: Darren K surname: McGuire fullname: McGuire, Darren K organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 7 givenname: Julia B surname: Lewis fullname: Lewis, Julia B organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 8 givenname: Matthew C surname: Riddle fullname: Riddle, Matthew C organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 9 givenname: Silvio E surname: Inzucchi fullname: Inzucchi, Silvio E organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 10 givenname: Mikhail N surname: Kosiborod fullname: Kosiborod, Mikhail N organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 11 givenname: David Z.I surname: Cherney fullname: Cherney, David Z.I organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 12 givenname: Jamie P surname: Dwyer fullname: Dwyer, Jamie P organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 13 givenname: Benjamin M surname: Scirica fullname: Scirica, Benjamin M organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 14 givenname: Clifford J surname: Bailey fullname: Bailey, Clifford J organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 15 givenname: Rafael surname: Díaz fullname: Díaz, Rafael organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 16 givenname: Kausik K surname: Ray fullname: Ray, Kausik K organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 17 givenname: Jacob A surname: Udell fullname: Udell, Jacob A organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 18 givenname: Renato D surname: Lopes fullname: Lopes, Renato D organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 19 givenname: Pablo surname: Lapuerta fullname: Lapuerta, Pablo organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) – sequence: 20 givenname: P. Gabriel surname: Steg fullname: Steg, P. Gabriel organization: From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B., C.P.C., B.M.S.); Colorado Prevention Center Clinical Research and Department of Medicine, Division of Cardiovascular Medicine, University of Colorado Anschutz Medical Campus, Aurora (M.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.); the University of Michigan, Ann Arbor (B.P.); Li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism, St. Michael’s Hospital, and the Departments of Medicine and Nutritional Sciences, University of Toronto (L.A.L.), and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division, Department of Medicine, Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.), University Health Network, University of Toronto — all in Toronto; the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas (D.K.M.), and Lexicon Pharmaceuticals, The Woodlands (P.L.) — both in Texas; Vanderbilt University Medical Center, Nashville (J.B.L., J.P.D.); the Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland (M.C.R.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City, Kansas City (M.N.K.); the School of Life and Health Sciences, Aston University, Birmingham (C.J.B.), and the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.) — both in the United Kingdom; the Department of Medicine, Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina (R.D.); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (R.D.L.); and Université de Paris, French Alliance for Cardiovascular Trials, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, INSERM Unité 1148, Paris (P.G.S.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33200891$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10NtLwzAUBvAgE3fRR1-lIIIv1aRpm-RR57zOC6jPJUtPXUabzCZD5l9vZFNwYAjkIb_vcPj6qGOsAYT2CT4hOMtPH0a391YmmGLC8y3UIxmlcZrivIN6GCc8TpmgXdR3bobDIanYQV1KE4y5ID10_my9fKt1VdtPbaJwn6TXYLyLPrSfRhdaTsCDi6Qpo-G0tUar6E6XBpbhz4F0sIu2K1k72Fu_A_R6OXoZXsfjx6ub4dk4VlRgH-eZ5IJXGCDHrKoyXgkqQGWghJQAWZlTXjIqOFY5p0wlTE5ESQUTkkggEzpAx6u589a-L8D5otFOQV1LA3bhiiTNSYhTigM93KAzu2hN2C4oxlhoK2NBHazVYtJAWcxb3ch2Wfy0E0C8Aqq1zrVQ_RKCi-_2iz_tB083vNI-1GmNb6Wu_00drVJN4woDs-Yf9wUMT5Fq |
| CitedBy_id | crossref_primary_10_3390_medicina60060912 crossref_primary_10_1007_s12325_022_02169_3 crossref_primary_10_1016_j_pharmthera_2022_108330 crossref_primary_10_1016_j_lfs_2023_121671 crossref_primary_10_1007_s40265_021_01573_3 crossref_primary_10_1002_ejhf_3292 crossref_primary_10_1016_j_metabol_2021_154799 crossref_primary_10_1002_ehf2_14297 crossref_primary_10_1093_ndt_gfae263 crossref_primary_10_1007_s00108_022_01297_w crossref_primary_10_1007_s00228_024_03631_7 crossref_primary_10_1016_j_eprac_2022_05_005 crossref_primary_10_1111_dom_16190 crossref_primary_10_3390_healthcare12232464 crossref_primary_10_1007_s00125_021_05529_w crossref_primary_10_14797_mdcvj_1155 crossref_primary_10_1093_ehjqcco_qcac040 crossref_primary_10_1016_j_jdiacomp_2022_108352 crossref_primary_10_1093_eurheartj_ehab094 crossref_primary_10_1016_j_talanta_2023_125156 crossref_primary_10_1097_MD_0000000000034693 crossref_primary_10_1177_11795468251347777 crossref_primary_10_1681_ASN_0000000540 crossref_primary_10_1186_s12933_020_01197_z crossref_primary_10_1002_cpt_2575 crossref_primary_10_1016_j_jnma_2025_08_110 crossref_primary_10_1016_j_jchf_2024_02_020 crossref_primary_10_4103_ijcm_ijcm_210_23 crossref_primary_10_1016_j_jacc_2023_08_050 crossref_primary_10_2337_dc22_0382 crossref_primary_10_1111_jdi_13915 crossref_primary_10_1161_HYPERTENSIONAHA_123_20598 crossref_primary_10_1093_ndt_gfaf132 crossref_primary_10_1056_NEJMra2115011 crossref_primary_10_1111_dom_15080 crossref_primary_10_1016_j_pcd_2022_02_002 crossref_primary_10_1097_MD_0000000000032489 crossref_primary_10_17925_HI_2023_17_2_5 crossref_primary_10_1002_ejhf_2172 crossref_primary_10_1186_s12933_025_02700_0 crossref_primary_10_1053_j_ajkd_2021_09_015 crossref_primary_10_1007_s00125_024_06293_3 crossref_primary_10_1002_ejhf_3024 crossref_primary_10_1016_j_diabres_2022_110161 crossref_primary_10_1002_ehf2_15136 crossref_primary_10_1186_s12933_024_02368_y crossref_primary_10_1016_j_semarthrit_2022_152058 crossref_primary_10_1016_j_cardfail_2021_04_023 crossref_primary_10_3390_jcdd9070225 crossref_primary_10_1016_j_rec_2022_04_019 crossref_primary_10_1001_jamanetworkopen_2021_42078 crossref_primary_10_1016_j_ejim_2023_10_008 crossref_primary_10_3390_biom15010039 crossref_primary_10_1016_j_ihj_2023_03_003 crossref_primary_10_59556_japi_71_0440 crossref_primary_10_1146_annurev_med_042921_102135 crossref_primary_10_14797_mdcvj_1120 crossref_primary_10_1007_s12325_021_01711_z crossref_primary_10_3390_ijms22041680 crossref_primary_10_1007_s11936_024_01048_0 crossref_primary_10_1016_j_jchf_2021_04_005 crossref_primary_10_1007_s11883_021_00952_1 crossref_primary_10_1016_j_jacc_2023_07_024 crossref_primary_10_1007_s10741_024_10385_y crossref_primary_10_1186_s12933_021_01213_w crossref_primary_10_1007_s13300_022_01228_w crossref_primary_10_1016_j_ando_2022_09_023 crossref_primary_10_1007_s11886_022_01677_6 crossref_primary_10_1038_s41581_022_00535_6 crossref_primary_10_1016_j_numecd_2025_104033 crossref_primary_10_1097_TP_0000000000005503 crossref_primary_10_1038_s41574_025_01170_4 crossref_primary_10_1111_dom_14805 crossref_primary_10_1007_s11906_023_01240_w crossref_primary_10_1002_ejhf_3240 crossref_primary_10_1053_j_ackd_2021_04_005 crossref_primary_10_1186_s12882_023_03339_3 crossref_primary_10_1002_ejhf_2397 crossref_primary_10_1056_NEJMe2033176 crossref_primary_10_1097_HJH_0000000000003280 crossref_primary_10_1016_j_cpcardiol_2023_101817 crossref_primary_10_1681_ASN_0000000752 crossref_primary_10_1186_s43094_024_00751_w crossref_primary_10_1016_j_diabres_2024_111816 crossref_primary_10_1111_jce_16344 crossref_primary_10_1111_bcpt_13739 crossref_primary_10_1007_s00228_021_03261_3 crossref_primary_10_1056_NEJMc2102961 crossref_primary_10_3390_ijms24032803 crossref_primary_10_1080_14728214_2023_2277762 crossref_primary_10_4239_wjd_v16_i6_104706 crossref_primary_10_1002_ptr_70059 crossref_primary_10_34067_KID_0001172021 crossref_primary_10_1093_ejendo_lvad078 crossref_primary_10_1210_clinem_dgaf295 crossref_primary_10_1016_j_neurot_2023_11_002 crossref_primary_10_1186_s12933_023_01798_4 crossref_primary_10_1172_JCI180078 crossref_primary_10_1097_FJC_0000000000001511 crossref_primary_10_2147_DDDT_S281602 crossref_primary_10_3389_fphar_2024_1372421 crossref_primary_10_1016_j_phrs_2021_105836 crossref_primary_10_2174_1381612829666230804103643 crossref_primary_10_3389_fendo_2022_900114 crossref_primary_10_1016_j_cardfail_2023_08_003 crossref_primary_10_1002_ejhf_2135 crossref_primary_10_1038_s41598_025_98997_8 crossref_primary_10_1186_s12933_022_01476_x crossref_primary_10_1007_s40620_023_01818_2 crossref_primary_10_1016_j_jacc_2024_01_040 crossref_primary_10_2147_DDDT_S372575 crossref_primary_10_1007_s40256_022_00528_7 crossref_primary_10_7759_cureus_35030 crossref_primary_10_1007_s11596_023_2765_y crossref_primary_10_3389_fphar_2024_1493590 crossref_primary_10_1038_s44161_023_00306_x crossref_primary_10_4330_wjc_v16_i10_550 crossref_primary_10_2215_CJN_0000000000000465 crossref_primary_10_1111_joim_20050 crossref_primary_10_1186_s12933_022_01481_0 crossref_primary_10_3389_fphar_2022_938391 crossref_primary_10_3389_fphar_2025_1558367 crossref_primary_10_1007_s11606_022_07428_1 crossref_primary_10_1016_j_diabres_2021_108648 crossref_primary_10_1002_ejhf_2116 crossref_primary_10_3390_ijms25041972 crossref_primary_10_1093_ndt_gfab167 crossref_primary_10_1038_s41419_022_05120_0 crossref_primary_10_1097_MD_0000000000026431 crossref_primary_10_1111_dom_14819 crossref_primary_10_3390_ijms241814243 crossref_primary_10_1016_j_jchf_2023_08_007 crossref_primary_10_1111_dom_15901 crossref_primary_10_1016_j_arr_2025_102834 crossref_primary_10_1016_S2213_8587_23_00291_7 crossref_primary_10_1016_j_jacc_2023_09_004 crossref_primary_10_1136_ard_2023_224242 crossref_primary_10_1093_eurheartj_ehab704 crossref_primary_10_1161_JAHA_124_034804 crossref_primary_10_1002_dmrr_3755 crossref_primary_10_1002_adtp_202300143 crossref_primary_10_1016_j_bbrc_2025_151338 crossref_primary_10_1002_ejhf_2333 crossref_primary_10_1016_S2213_8587_24_00102_5 crossref_primary_10_1007_s40265_024_02090_9 crossref_primary_10_1016_j_phrs_2021_106049 crossref_primary_10_3390_jcm12123925 crossref_primary_10_1161_JAHA_122_025973 crossref_primary_10_2215_CJN_0000000000000414 crossref_primary_10_1016_j_metabol_2022_155332 crossref_primary_10_1016_j_jchf_2021_06_017 crossref_primary_10_1016_j_eurpolymj_2021_110648 crossref_primary_10_1007_s00125_022_05773_8 crossref_primary_10_3389_fcvm_2023_1046194 crossref_primary_10_1016_j_kint_2022_06_013 crossref_primary_10_1007_s11428_023_01047_y crossref_primary_10_1016_j_jacadv_2024_101024 crossref_primary_10_3389_fcvm_2024_1379765 crossref_primary_10_3390_life12101663 crossref_primary_10_1016_j_jchf_2021_06_011 crossref_primary_10_1016_j_ahj_2022_05_010 crossref_primary_10_1080_17446651_2022_2099838 crossref_primary_10_3390_ijms22189852 crossref_primary_10_3389_fphar_2021_751496 crossref_primary_10_3390_ph18050735 crossref_primary_10_1007_s00210_024_03063_1 crossref_primary_10_1161_JAHA_123_033236 crossref_primary_10_1111_dom_15734 crossref_primary_10_1016_j_ejmech_2025_117977 crossref_primary_10_3390_cells11233913 crossref_primary_10_1007_s11695_022_06328_x crossref_primary_10_2147_IJGM_S447921 crossref_primary_10_1111_dom_14859 crossref_primary_10_1007_s10557_025_07723_z crossref_primary_10_1093_eurheartj_ehae190 crossref_primary_10_1002_ehf2_13148 crossref_primary_10_1007_s11560_024_00821_3 crossref_primary_10_1016_j_jacc_2021_11_027 crossref_primary_10_1093_ajhp_zxaf045 crossref_primary_10_1038_s41581_024_00836_y crossref_primary_10_7759_cureus_82458 crossref_primary_10_1093_cvr_cvae047 crossref_primary_10_1093_eurheartj_ehae179 crossref_primary_10_1016_S2213_8587_23_00009_8 crossref_primary_10_1016_j_phymed_2024_156351 crossref_primary_10_1161_CIRCRESAHA_122_321748 crossref_primary_10_3390_cells10102699 crossref_primary_10_1186_s12933_024_02255_6 crossref_primary_10_1016_j_kint_2022_06_008 crossref_primary_10_1002_ehf2_14248 crossref_primary_10_2147_IJNRD_S387262 crossref_primary_10_1016_j_cpcardiol_2022_101582 crossref_primary_10_1093_ehjcvp_pvac001 crossref_primary_10_2337_dc21_ad09a crossref_primary_10_1186_s12933_021_01362_y crossref_primary_10_1186_s13578_024_01203_x crossref_primary_10_1016_j_cardfail_2021_07_011 crossref_primary_10_1016_j_metabol_2024_155931 crossref_primary_10_1038_s41440_021_00766_3 crossref_primary_10_1016_j_diabres_2022_109871 crossref_primary_10_1016_j_ebiom_2022_104215 crossref_primary_10_1097_MNH_0000000000000929 crossref_primary_10_1007_s10557_021_07203_0 crossref_primary_10_1177_00033197231183229 crossref_primary_10_1007_s00592_022_02022_7 crossref_primary_10_1016_j_jchf_2024_05_011 crossref_primary_10_3390_antiox11122500 crossref_primary_10_1016_j_dsx_2022_102661 crossref_primary_10_3389_fcvm_2022_942125 crossref_primary_10_1186_s12933_023_02035_8 crossref_primary_10_3389_fcvm_2022_875327 crossref_primary_10_1038_s41392_023_01400_z crossref_primary_10_1007_s10557_021_07291_y crossref_primary_10_1111_dom_14675 crossref_primary_10_1111_dom_15764 crossref_primary_10_1111_dom_15765 crossref_primary_10_1007_s10741_021_10211_9 crossref_primary_10_1007_s11886_022_01637_0 crossref_primary_10_1093_eurheartj_ehab887 crossref_primary_10_3390_biomedicines10123294 crossref_primary_10_1111_dme_15464 crossref_primary_10_1161_CIRCRESAHA_122_321762 crossref_primary_10_3389_fcvm_2023_1273781 crossref_primary_10_1093_ehjcvp_pvab056 crossref_primary_10_1080_14656566_2025_2464905 crossref_primary_10_1080_14656566_2022_2113385 crossref_primary_10_1186_s12933_024_02328_6 crossref_primary_10_1161_JAHA_120_019918 crossref_primary_10_3389_fcvm_2024_1339094 crossref_primary_10_1186_s12882_024_03833_2 crossref_primary_10_1016_j_amjcard_2021_07_035 crossref_primary_10_1080_17446651_2022_2014322 crossref_primary_10_3390_medicina60081198 crossref_primary_10_1016_j_jacc_2021_08_009 crossref_primary_10_1007_s10557_021_07301_z crossref_primary_10_1080_0886022X_2025_2552913 crossref_primary_10_1007_s40261_021_01098_3 crossref_primary_10_3390_medicina61020202 crossref_primary_10_1080_0886022X_2023_2217287 crossref_primary_10_3390_app13084924 crossref_primary_10_1161_CIRCULATIONAHA_121_052792 crossref_primary_10_1016_j_xkme_2021_04_009 crossref_primary_10_1097_MS9_0000000000003357 crossref_primary_10_1007_s40256_021_00495_5 crossref_primary_10_1111_dom_16606 crossref_primary_10_1007_s40256_021_00484_8 crossref_primary_10_1093_ehjcvp_pvad012 crossref_primary_10_1007_s13300_022_01276_2 crossref_primary_10_1111_dom_15565 crossref_primary_10_1007_s10741_023_10324_3 crossref_primary_10_1007_s12265_022_10302_4 crossref_primary_10_1093_eurheartj_suab066 crossref_primary_10_1161_CIR_0000000000001040 crossref_primary_10_15829_1560_4071_2021_4235 crossref_primary_10_4103_ijp_ijp_342_21 crossref_primary_10_3389_fcvm_2021_810791 crossref_primary_10_1016_j_pharmthera_2023_108481 crossref_primary_10_2174_0113895575325210240805092741 crossref_primary_10_1097_FJC_0000000000001176 crossref_primary_10_2174_1381612829666230217143324 crossref_primary_10_3390_ijms231911987 crossref_primary_10_12968_hmed_2024_0546 crossref_primary_10_1016_j_carres_2025_109408 crossref_primary_10_1016_j_jchf_2024_04_018 crossref_primary_10_1097_CRD_0000000000000760 crossref_primary_10_1007_s10741_024_10454_2 crossref_primary_10_1177_20420188211044945 crossref_primary_10_1093_eurheartj_ehab876 crossref_primary_10_33678_cor_2024_025 crossref_primary_10_1161_JAHA_123_030578 crossref_primary_10_1007_s13300_025_01715_w crossref_primary_10_1177_1358863X221143811 crossref_primary_10_1136_heartjnl_2020_318004 crossref_primary_10_1186_s12933_023_01911_7 crossref_primary_10_1016_j_amjmed_2021_04_024 crossref_primary_10_1016_S0140_6736_25_01384_4 crossref_primary_10_1111_dom_15789 crossref_primary_10_2337_dc21_2166 crossref_primary_10_3390_jcm14082833 crossref_primary_10_1097_MNH_0000000000000703 crossref_primary_10_1055_a_2481_2004 crossref_primary_10_1007_s42000_025_00702_x crossref_primary_10_1053_j_jvca_2025_06_015 crossref_primary_10_1007_s10741_021_10083_z crossref_primary_10_3390_healthcare12070753 crossref_primary_10_15829_1560_4071_2024_5841 crossref_primary_10_1093_ckj_sfac066 crossref_primary_10_1016_j_ejps_2023_106644 crossref_primary_10_1186_s12933_024_02154_w crossref_primary_10_1186_s12933_022_01646_x crossref_primary_10_3390_ijms23137261 crossref_primary_10_3389_fendo_2022_1078686 crossref_primary_10_3389_fendo_2021_743807 crossref_primary_10_1111_dom_70118 crossref_primary_10_7326_M22_2904 crossref_primary_10_1097_MNH_0000000000000935 crossref_primary_10_1161_JAHA_122_029058 crossref_primary_10_1055_a_1332_3750 crossref_primary_10_1161_JAHA_123_031805 crossref_primary_10_1186_s12933_022_01575_9 crossref_primary_10_1007_s15027_021_3544_y crossref_primary_10_1186_s12913_024_11520_z crossref_primary_10_1186_s12933_024_02181_7 crossref_primary_10_1016_j_metabol_2021_154838 crossref_primary_10_1016_j_eclinm_2025_103462 crossref_primary_10_3390_biomedicines11082236 crossref_primary_10_1111_dom_15122 crossref_primary_10_3389_fendo_2023_1238399 crossref_primary_10_1016_j_pcad_2025_04_004 crossref_primary_10_1038_s41598_025_93811_x crossref_primary_10_3390_ijms22020660 crossref_primary_10_3390_nu15061384 crossref_primary_10_5527_wjn_v12_i5_182 crossref_primary_10_3390_antiox10081190 crossref_primary_10_2337_dc22_0772 crossref_primary_10_1161_CIRCULATIONAHA_124_069695 crossref_primary_10_1016_j_jcte_2024_100335 crossref_primary_10_1016_j_amjmed_2023_04_019 crossref_primary_10_3390_ijms222312677 crossref_primary_10_1016_j_jacadv_2025_101615 crossref_primary_10_3390_biomedicines12040806 crossref_primary_10_31146_1682_8658_ecg_230_10_11_35 crossref_primary_10_1007_s00059_024_05286_7 crossref_primary_10_1016_j_diabres_2023_110726 crossref_primary_10_1080_00325481_2024_2418795 crossref_primary_10_1016_j_amjmed_2023_04_035 crossref_primary_10_1038_s41574_022_00776_2 crossref_primary_10_1016_j_diabres_2022_110200 crossref_primary_10_1002_ehf2_13905 crossref_primary_10_7759_cureus_21768 crossref_primary_10_1177_10600280231211179 crossref_primary_10_3390_toxins14030210 crossref_primary_10_1007_s00108_021_01083_0 crossref_primary_10_33590_emj_22_00026 crossref_primary_10_3390_jcm11010137 crossref_primary_10_2147_DDDT_S418321 crossref_primary_10_1016_j_diabres_2025_112278 crossref_primary_10_1053_j_jvca_2025_05_010 crossref_primary_10_1016_j_obpill_2023_100071 crossref_primary_10_3389_fphar_2024_1373314 crossref_primary_10_3389_fphys_2021_755060 crossref_primary_10_1177_20420188211042145 crossref_primary_10_3390_jcm12082824 crossref_primary_10_1016_j_cardfail_2024_04_009 crossref_primary_10_1111_jvp_13472 crossref_primary_10_1210_clinem_dgab639 crossref_primary_10_1186_s12933_025_02750_4 crossref_primary_10_1016_j_ejphar_2022_175354 crossref_primary_10_1016_j_ejphar_2024_176858 crossref_primary_10_5049_EBP_2021_19_2_19 crossref_primary_10_1007_s00592_022_01943_7 crossref_primary_10_4330_wjc_v14_i11_599 crossref_primary_10_1080_17425255_2022_2105693 crossref_primary_10_3389_fendo_2023_1216160 crossref_primary_10_1111_dom_16011 crossref_primary_10_1016_j_diabres_2021_109146 crossref_primary_10_18553_jmcp_2025_31_7_641 crossref_primary_10_1016_j_diabres_2025_112219 crossref_primary_10_1016_j_ajpc_2025_101061 crossref_primary_10_1016_S0140_6736_21_00536_5 crossref_primary_10_1093_ajhp_zxac129 crossref_primary_10_3389_fphar_2024_1443045 crossref_primary_10_1007_s00592_022_01989_7 crossref_primary_10_1080_14779072_2023_2159810 crossref_primary_10_1080_17512433_2023_2173574 crossref_primary_10_1161_JAHA_124_037207 crossref_primary_10_1007_s12471_021_01579_2 crossref_primary_10_1007_s10557_021_07243_6 crossref_primary_10_1111_dom_15171 crossref_primary_10_1186_s12933_024_02424_7 crossref_primary_10_1016_j_phrs_2021_105530 crossref_primary_10_3389_fendo_2024_1429261 crossref_primary_10_1016_j_jcjd_2022_11_002 crossref_primary_10_1111_ctr_70233 crossref_primary_10_1016_j_ejps_2025_107045 crossref_primary_10_1007_s11357_022_00610_7 crossref_primary_10_3389_fcvm_2022_857952 crossref_primary_10_1111_cts_13222 crossref_primary_10_3389_fendo_2025_1629488 crossref_primary_10_1016_j_ijcard_2021_05_050 crossref_primary_10_3390_ijms25031574 crossref_primary_10_1093_ajh_hpad073 crossref_primary_10_3390_jcm11071904 crossref_primary_10_1007_s15027_023_3012_y crossref_primary_10_1016_j_cmet_2021_10_011 crossref_primary_10_1038_s41598_023_48716_y crossref_primary_10_1186_s12933_021_01401_8 crossref_primary_10_1016_j_dsx_2021_01_006 crossref_primary_10_1038_s41598_025_99446_2 crossref_primary_10_1007_s11886_023_01961_z crossref_primary_10_1016_j_jacc_2024_06_036 crossref_primary_10_1016_j_jacadv_2023_100349 crossref_primary_10_1002_advs_202100827 crossref_primary_10_1007_s40265_021_01538_6 crossref_primary_10_1080_17512433_2024_2390921 crossref_primary_10_1007_s13300_025_01696_w crossref_primary_10_3389_fcvm_2021_679124 crossref_primary_10_1001_jamanetworkopen_2024_32296 crossref_primary_10_3390_biomedicines11020279 crossref_primary_10_1016_j_diabet_2024_101594 crossref_primary_10_2337_dc21_1722 crossref_primary_10_1111_nyas_15259 crossref_primary_10_3389_fphar_2022_986186 crossref_primary_10_1007_s00232_021_00192_z crossref_primary_10_1007_s10557_021_07309_5 crossref_primary_10_1097_CCM_0000000000005869 crossref_primary_10_1016_j_lpm_2023_104219 crossref_primary_10_2174_1381612829666230703161058 crossref_primary_10_1093_eurheartj_ehad389 crossref_primary_10_1038_s44161_025_00657_7 crossref_primary_10_1093_ehjqcco_qcab072 crossref_primary_10_1097_FJC_0000000000001659 crossref_primary_10_1016_j_hfc_2022_03_010 crossref_primary_10_1007_s40256_025_00760_x crossref_primary_10_1001_jamanetworkopen_2025_4740 crossref_primary_10_1002_ehf2_15036 crossref_primary_10_2337_dc23_S010 crossref_primary_10_1111_eci_70080 crossref_primary_10_1371_journal_pone_0261986 crossref_primary_10_1186_s12933_023_01788_6 crossref_primary_10_1007_s10741_021_10186_7 crossref_primary_10_3390_ijms24119760 crossref_primary_10_1080_17446651_2022_2099373 crossref_primary_10_1016_j_hfc_2022_03_008 crossref_primary_10_1016_j_hfc_2022_03_006 crossref_primary_10_1016_j_hfc_2022_03_007 crossref_primary_10_1111_dom_15185 crossref_primary_10_1111_eci_14335 crossref_primary_10_1007_s40264_022_01166_3 crossref_primary_10_1016_j_phrs_2022_106062 crossref_primary_10_1080_17512433_2022_2051480 crossref_primary_10_15212_bioi_2024_0137 crossref_primary_10_7759_cureus_37388 crossref_primary_10_1111_nep_14167 crossref_primary_10_1001_jama_2024_27402 crossref_primary_10_1038_s41581_022_00645_1 crossref_primary_10_3390_medicina60091542 crossref_primary_10_1111_dom_16282 crossref_primary_10_3390_life13040951 crossref_primary_10_1177_10742484231162248 crossref_primary_10_1186_s12916_025_04018_w crossref_primary_10_1002_ejhf_2286 crossref_primary_10_2174_0929867330666221227091943 crossref_primary_10_1007_s40200_024_01545_w crossref_primary_10_1111_1753_0407_13182 crossref_primary_10_1177_21501319241259905 crossref_primary_10_2337_dc20_3007 crossref_primary_10_1002_ejhf_2279 crossref_primary_10_3389_fendo_2022_968478 crossref_primary_10_4330_wjc_v13_i9_464 crossref_primary_10_1007_s00508_023_02186_4 crossref_primary_10_1007_s40262_024_01443_7 crossref_primary_10_1056_NEJMoa2110956 crossref_primary_10_1152_ajprenal_00119_2025 crossref_primary_10_7759_cureus_31898 crossref_primary_10_7326_M21_0651 crossref_primary_10_2215_CJN_0000000000000159 crossref_primary_10_1016_j_diabres_2024_111933 crossref_primary_10_1177_87551225241261040 crossref_primary_10_1002_psb_2014 crossref_primary_10_1186_s12933_023_02019_8 crossref_primary_10_1186_s12882_024_03720_w crossref_primary_10_1093_eurheartj_ehaf314 crossref_primary_10_1186_s12933_024_02180_8 crossref_primary_10_1016_j_jacc_2025_06_047 crossref_primary_10_1111_dom_16079 crossref_primary_10_1007_s00392_021_01867_2 crossref_primary_10_3389_fimmu_2022_977413 crossref_primary_10_1007_s12265_022_10220_5 crossref_primary_10_1007_s12561_025_09488_3 crossref_primary_10_1111_dom_16077 crossref_primary_10_1007_s11255_022_03117_4 crossref_primary_10_1055_a_2096_7448 crossref_primary_10_1016_S2213_8587_23_00322_4 crossref_primary_10_31083_j_fbl2805103 crossref_primary_10_1007_s00125_022_05787_2 crossref_primary_10_1080_00325481_2021_2002580 crossref_primary_10_1007_s00059_022_05134_6 crossref_primary_10_1002_ejhf_3347 crossref_primary_10_23736_S0026_4806_25_09607_7 crossref_primary_10_70389_PJBS_100009 crossref_primary_10_1080_14740338_2023_2182290 crossref_primary_10_1007_s11883_022_01038_2 crossref_primary_10_1111_dom_14715 crossref_primary_10_1111_joim_13620 crossref_primary_10_3389_fendo_2023_1236404 crossref_primary_10_3389_fcvm_2021_691907 crossref_primary_10_1016_j_cpcardiol_2023_101597 crossref_primary_10_1111_pedi_13444 crossref_primary_10_1007_s00109_021_02037_7 crossref_primary_10_1007_s40261_021_01095_6 crossref_primary_10_2337_dc22_S010 crossref_primary_10_1097_FJC_0000000000001248 crossref_primary_10_1186_s13098_024_01325_9 crossref_primary_10_1002_ejhf_2249 crossref_primary_10_3389_fendo_2024_1376446 crossref_primary_10_3390_ijms23147966 crossref_primary_10_1007_s12325_021_01989_z crossref_primary_10_1097_MNH_0000000000000887 crossref_primary_10_1016_j_rec_2024_01_011 crossref_primary_10_1161_JAHA_123_032463 crossref_primary_10_1093_cvr_cvad096 crossref_primary_10_1155_2022_4635171 crossref_primary_10_1093_eurheartj_ehaf167 crossref_primary_10_1007_s40261_021_01105_7 crossref_primary_10_1080_17446651_2023_2210673 crossref_primary_10_1186_s12933_022_01601_w crossref_primary_10_1159_000542132 crossref_primary_10_1210_jendso_bvac191 crossref_primary_10_1093_eurheartj_ehab832 crossref_primary_10_1007_s00592_023_02154_4 crossref_primary_10_1161_JAHA_123_031586 crossref_primary_10_1177_01410768231198442 crossref_primary_10_1007_s10741_021_10111_y crossref_primary_10_1161_JAHA_123_030495 crossref_primary_10_1002_ehf2_15408 crossref_primary_10_1210_clinem_dgaf133 crossref_primary_10_1002_ehf2_14555 crossref_primary_10_1007_s11428_023_01144_y crossref_primary_10_3389_fphar_2022_919974 crossref_primary_10_1111_nep_13917 crossref_primary_10_1016_j_ccl_2021_04_007 crossref_primary_10_1111_dom_14702 crossref_primary_10_3390_ijms231911203 crossref_primary_10_1186_s12933_021_01430_3 crossref_primary_10_1016_j_ccl_2021_04_001 crossref_primary_10_1111_bcp_14825 crossref_primary_10_1016_S2213_8587_23_00128_6 crossref_primary_10_1002_ehf2_13472 crossref_primary_10_1007_s40618_024_02351_0 crossref_primary_10_3389_fpubh_2024_1412874 crossref_primary_10_1016_j_ejim_2021_03_001 crossref_primary_10_1186_s41100_024_00523_5 crossref_primary_10_3390_ijms24108643 crossref_primary_10_1016_j_pcd_2025_05_005 crossref_primary_10_15829_1728_8800_2024_3996 crossref_primary_10_3390_jcm13216509 crossref_primary_10_3389_fcvm_2023_1143658 crossref_primary_10_7759_cureus_75802 crossref_primary_10_1111_dom_14513 crossref_primary_10_1186_s12933_022_01516_6 crossref_primary_10_1007_s12020_023_03618_x crossref_primary_10_1186_s12933_021_01254_1 crossref_primary_10_1093_ndt_gfac165 crossref_primary_10_1055_a_2546_0353 crossref_primary_10_3390_ijms23073651 crossref_primary_10_1186_s13098_024_01547_x crossref_primary_10_1016_j_nefroe_2024_03_011 crossref_primary_10_1007_s12181_024_00689_6 crossref_primary_10_3390_jcm13061797 crossref_primary_10_1093_eurheartj_ehad192 crossref_primary_10_1097_CRD_0000000000000484 crossref_primary_10_1093_eurheartj_ehae040 crossref_primary_10_1016_j_ijcard_2025_133079 crossref_primary_10_1093_eurheartj_ehad195 crossref_primary_10_1016_j_mcna_2023_11_003 crossref_primary_10_1097_MD_0000000000027802 crossref_primary_10_3390_jcdd10080322 crossref_primary_10_1038_s41392_024_01951_9 crossref_primary_10_1186_s13643_025_02766_7 crossref_primary_10_3389_fmed_2021_728089 crossref_primary_10_1111_dom_14976 crossref_primary_10_1186_s13098_022_00929_3 crossref_primary_10_3389_fphar_2024_1419729 crossref_primary_10_1177_17539447241289067 crossref_primary_10_1016_j_arr_2025_102751 crossref_primary_10_1002_ehf2_14355 crossref_primary_10_1002_edm2_303 crossref_primary_10_1016_j_phrs_2022_106261 crossref_primary_10_1161_CIRCRESAHA_121_318159 crossref_primary_10_2337_dc24_S010 crossref_primary_10_2215_CJN_0000000000000568 crossref_primary_10_1016_j_cjca_2022_04_029 crossref_primary_10_1186_s12933_023_01877_6 crossref_primary_10_3748_wjg_v28_i39_5691 crossref_primary_10_1111_jgs_17895 crossref_primary_10_1007_s11892_021_01442_z crossref_primary_10_3390_jcm13226993 crossref_primary_10_2337_dc24_S009 crossref_primary_10_1002_ejhf_2894 crossref_primary_10_1111_dom_14986 crossref_primary_10_1080_07853890_2023_2203517 crossref_primary_10_1080_14779072_2022_2057949 crossref_primary_10_1016_j_nephro_2020_12_006 crossref_primary_10_1093_eurjpc_zwad356 crossref_primary_10_1016_S2213_8587_25_00001_4 crossref_primary_10_1111_dom_14555 crossref_primary_10_3390_jcm13051375 crossref_primary_10_1093_eurheartj_ehad718 crossref_primary_10_1007_s11883_023_01172_5 crossref_primary_10_1111_dom_14327 crossref_primary_10_1016_j_pcad_2023_10_003 crossref_primary_10_2337_dci22_0034 crossref_primary_10_1002_ehf2_14987 crossref_primary_10_1152_ajpendo_00034_2025 crossref_primary_10_1111_dom_70010 crossref_primary_10_3390_life12111829 crossref_primary_10_1007_s11892_022_01471_2 crossref_primary_10_1093_eurheartj_ehab798 crossref_primary_10_1371_journal_pone_0295059 crossref_primary_10_1016_j_dsx_2023_102804 crossref_primary_10_2337_dc25_S009 crossref_primary_10_1097_MD_0000000000027362 crossref_primary_10_1007_s40265_021_01559_1 crossref_primary_10_1016_S0140_6736_22_02074_8 crossref_primary_10_1016_j_diabet_2023_101419 crossref_primary_10_1210_clinem_dgad113 crossref_primary_10_3389_fcvm_2022_1067806 crossref_primary_10_3390_biomedicines13030728 crossref_primary_10_3389_fendo_2024_1499681 crossref_primary_10_3389_fcvm_2022_1039348 crossref_primary_10_1016_j_jphs_2025_09_008 crossref_primary_10_1007_s11428_023_01109_1 crossref_primary_10_3389_fendo_2021_749010 crossref_primary_10_3390_ijms26178202 crossref_primary_10_2337_dc25_S010 crossref_primary_10_3389_fphar_2025_1585491 crossref_primary_10_1007_s00125_022_05694_6 crossref_primary_10_1016_j_amjcard_2022_10_027 crossref_primary_10_1080_07328303_2022_2027433 crossref_primary_10_3390_jcm12206462 crossref_primary_10_1172_JCI164486 crossref_primary_10_1016_j_mmm_2025_04_004 crossref_primary_10_1097_MJT_0000000000001452 crossref_primary_10_1093_eurjpc_zwab189 crossref_primary_10_3389_fphar_2023_1303694 crossref_primary_10_1007_s10741_024_10453_3 crossref_primary_10_1097_BOR_0000000000001002 crossref_primary_10_1001_jamanetworkopen_2022_43201 crossref_primary_10_1016_j_jacasi_2021_08_003 crossref_primary_10_1016_j_cjca_2022_05_011 crossref_primary_10_1038_s41598_024_52331_w crossref_primary_10_1097_MD_0000000000025121 crossref_primary_10_1016_j_ijcard_2022_09_009 crossref_primary_10_1016_j_metabol_2021_154918 crossref_primary_10_3390_pharmaceutics15071995 crossref_primary_10_1016_j_bioorg_2021_105342 crossref_primary_10_1111_dom_15200 crossref_primary_10_1016_j_jjcc_2022_02_008 crossref_primary_10_1053_j_ajkd_2023_09_003 crossref_primary_10_1016_j_jacasi_2022_02_004 crossref_primary_10_1111_dom_15203 crossref_primary_10_1093_ehjcvp_pvae013 crossref_primary_10_1111_dom_14599 crossref_primary_10_1002_ejhf_2720 crossref_primary_10_4239_wjd_v16_i4_102390 crossref_primary_10_1016_j_biopha_2024_116650 crossref_primary_10_1111_nep_70030 crossref_primary_10_1016_j_heliyon_2023_e22423 crossref_primary_10_1093_cvr_cvab271 crossref_primary_10_1111_dom_15696 crossref_primary_10_2215_CJN_20211220 crossref_primary_10_1186_s12933_023_02023_y crossref_primary_10_3389_fendo_2023_1174692 crossref_primary_10_1093_ehjcvp_pvae003 crossref_primary_10_1038_s41569_020_00486_0 crossref_primary_10_3389_fcimb_2022_1073118 crossref_primary_10_4236_health_2021_1312102 crossref_primary_10_1007_s11428_022_00921_5 crossref_primary_10_1186_s40001_022_00945_z crossref_primary_10_1016_j_jacc_2022_03_353 crossref_primary_10_1161_JAHA_121_022222 crossref_primary_10_1007_s40265_021_01655_2 crossref_primary_10_4330_wjc_v16_i5_240 crossref_primary_10_3390_life13041024 crossref_primary_10_2215_CJN_0000000693 crossref_primary_10_1093_eurheartj_ehab751 crossref_primary_10_1161_CIRCULATIONAHA_121_056824 crossref_primary_10_3389_fendo_2023_1199960 crossref_primary_10_1155_2024_9985836 crossref_primary_10_1016_j_diabres_2022_109927 crossref_primary_10_1111_1753_0407_70044 crossref_primary_10_1016_j_atherosclerosis_2024_117560 crossref_primary_10_1093_ckj_sfab096 crossref_primary_10_1007_s13300_022_01242_y crossref_primary_10_2459_JCM_0000000000001504 crossref_primary_10_1111_bcp_16139 crossref_primary_10_2337_dci22_0014 crossref_primary_10_14814_phy2_15836 crossref_primary_10_1016_j_ejphar_2021_174272 crossref_primary_10_1016_j_bcp_2022_115349 crossref_primary_10_3389_fcvm_2021_636152 crossref_primary_10_1097_MNH_0000000000000811 crossref_primary_10_1177_10600280231154021 crossref_primary_10_1016_j_ejim_2021_11_008 crossref_primary_10_1080_0886022X_2025_2496980 crossref_primary_10_1093_eurheartj_ehab136 crossref_primary_10_1161_CIRCULATIONAHA_124_069568 crossref_primary_10_1038_s41598_023_42989_z crossref_primary_10_1016_j_xkme_2024_100851 crossref_primary_10_1111_dom_15009 crossref_primary_10_3389_fimmu_2023_1213473 crossref_primary_10_1080_14656566_2023_2204188 crossref_primary_10_1016_j_jcjd_2021_12_005 crossref_primary_10_1016_j_jdiacomp_2021_108101 crossref_primary_10_17925_HI_2023_17_2_12 crossref_primary_10_3389_fcvm_2025_1482918 crossref_primary_10_1007_s00592_024_02289_y crossref_primary_10_1016_j_jchf_2023_05_026 crossref_primary_10_1093_eurheartj_ehab368 crossref_primary_10_1002_mdc3_13893 crossref_primary_10_1007_s11883_022_01042_6 crossref_primary_10_1038_s41366_023_01429_8 crossref_primary_10_1007_s10557_023_07469_6 crossref_primary_10_1016_j_cmet_2021_02_016 crossref_primary_10_1016_j_lpm_2023_104185 crossref_primary_10_1038_s41401_022_00889_4 crossref_primary_10_1093_eurheartj_ehab360 crossref_primary_10_1080_10408363_2021_1993439 crossref_primary_10_1097_XCE_0000000000000284 crossref_primary_10_1016_j_jacc_2021_03_298 crossref_primary_10_3390_ijms24010351 crossref_primary_10_1111_dom_15019 crossref_primary_10_1007_s11845_023_03474_8 crossref_primary_10_3389_fphys_2022_1028486 crossref_primary_10_1007_s11936_021_00900_x crossref_primary_10_1111_dom_15251 crossref_primary_10_1038_s41598_024_84118_4 crossref_primary_10_1161_CIRCULATIONAHA_121_054442 crossref_primary_10_1080_13543784_2024_2326025 crossref_primary_10_1016_j_metabol_2021_154937 crossref_primary_10_1111_dom_14374 crossref_primary_10_1080_00015385_2023_2250949 crossref_primary_10_1007_s13679_023_00522_3 crossref_primary_10_57264_cer_2023_0190 crossref_primary_10_1016_j_medj_2021_10_004 crossref_primary_10_1093_eurheartjsupp_suaf070 crossref_primary_10_1146_annurev_pharmtox_052120_014725 crossref_primary_10_1161_HYPERTENSIONAHA_121_17005 crossref_primary_10_2217_fca_2020_0210 crossref_primary_10_1016_j_intimp_2025_115461 crossref_primary_10_1016_j_ihj_2024_07_005 crossref_primary_10_3389_fcvm_2022_1041200 crossref_primary_10_1007_s40256_022_00545_6 crossref_primary_10_1093_eurheartj_ehae602 crossref_primary_10_1016_j_hfc_2022_07_001 crossref_primary_10_3390_ijms24032988 crossref_primary_10_1111_dom_15047 crossref_primary_10_1016_j_ejim_2021_12_018 crossref_primary_10_1002_ehf2_13841 crossref_primary_10_1080_14740338_2023_2188190 crossref_primary_10_1111_dom_16371 crossref_primary_10_1016_j_freeradbiomed_2023_08_013 crossref_primary_10_1007_s10741_024_10388_9 crossref_primary_10_1093_ehjcvp_pvae093 crossref_primary_10_1161_STR_0000000000000475 crossref_primary_10_1093_eurheartj_ehac417 crossref_primary_10_1186_s12933_023_01773_z crossref_primary_10_14814_phy2_70217 crossref_primary_10_1016_S2213_8587_24_00362_0 crossref_primary_10_1111_dom_16147 crossref_primary_10_3389_fphar_2025_1583267 crossref_primary_10_1111_dom_16385 crossref_primary_10_1186_s12933_021_01281_y crossref_primary_10_1055_a_1971_3381 crossref_primary_10_1016_j_jacc_2023_04_034 crossref_primary_10_1093_eurheartj_ehac683 crossref_primary_10_21615_cesmedicina_6672 crossref_primary_10_3390_foods14122049 crossref_primary_10_1007_s11255_023_03789_6 crossref_primary_10_1016_j_kint_2023_10_018 crossref_primary_10_3390_biomedicines12071456 crossref_primary_10_1007_s11886_024_02055_0 crossref_primary_10_1186_s12933_022_01676_5 crossref_primary_10_17925_HI_2021_15_1_42 crossref_primary_10_3390_pharmaceutics14081730 crossref_primary_10_1159_000534174 crossref_primary_10_1080_14740338_2021_1898585 crossref_primary_10_1007_s13577_023_01007_0 crossref_primary_10_7759_cureus_88561 |
| Cites_doi | 10.1016/j.jacc.2018.08.2202 10.2337/dc18-0343 10.1001/jamacardio.2016.3030 10.1161/CIRCULATIONAHA.119.041181 10.1016/S2213-8587(15)00044-3 10.2337/dc18-0342 10.1007/s10985-019-09462-4 10.1161/CIRCULATIONAHA.119.040130 10.1161/CIRCULATIONAHA.114.014796 10.1139/cjpp-2018-0359 10.2337/dc18-1959 10.1016/j.bbrc.2020.01.015 10.1016/j.jacc.2020.07.051 10.1161/JAHA.120.018274 10.1161/CIRCULATIONAHA.114.010389 10.1056/NEJMoa2024816 10.1056/NEJMoa1611925 10.1038/s41569-020-00439-7 10.1056/NEJMoa1708337 10.2337/dci19-0074 10.1056/NEJMoa1504720 10.1016/j.jacbts.2018.01.010 10.1016/j.jacc.2018.07.061 10.1001/jama.2010.1322 10.1111/dom.14127 10.1002/sim.4780131709 10.1056/NEJMoa1911303 10.2337/dc14-2806 10.1056/NEJMoa2004967 10.2337/dc19-1410 10.1016/j.cmet.2019.08.015 10.2337/dc14-1850 10.1161/CIRCULATIONAHA.119.042375 10.1056/NEJMoa1307684 10.1016/S0140-6736(18)32590-X 10.1210/clinem/dgz258 10.1056/NEJMoa1007964 10.1001/jama.297.11.1197 10.1161/CIRCHEARTFAILURE.119.006720 10.1016/j.cmet.2018.11.010 10.1001/jama.295.2.180 10.1056/NEJMoa1811744 10.1016/j.cmet.2019.10.008 10.1016/j.jacc.2015.11.027 10.1056/NEJMoa2022190 10.1016/j.jacc.2020.05.041 10.1016/S0140-6736(18)31184-X 10.1056/NEJMoa1812389 10.1093/ndt/gfz294 |
| ContentType | Journal Article |
| Contributor | Chumburidze, Vakhtang Marcus, Jill Zahger, Doron Francis, Gary S Goldberg Eliaschewitz, Freddy Mathews, Robin Bailey, Clifford J Milenkovic, Tatjana Marandi, Toomas Middleton, John P Guja, Cristian Martinka, Emil Jeong, MyungHo Brown, Linley Risstad, Hilde Lalić, Neboiša Sposato, Luciano A Weber, Thomas J Povsic, Thomas J McGarrah, Robert W Young, James B Inzucchi, Silvio E Merkely, Béla Peter Lewis, James Shih, Weichung Joe Díaz, Rafael Žilaitienė, Birutė Mehta, Rajendra H Udell, Jacob A Murin, Jan Lewis, Julia B Tankova, Tsvetalina Mann, Johannes F E Kosiborod, Mikhail N Lakey, Wanda C Seufert, Jochen Burgess, Lesley Jean Lejnieks, Aivars Kong, David F Hayden, Nikieia Green, Jennifer B Cooper, Mark Jones, W Schuyler Jordan, J Dedrick Leeper, Nicholas Stournaras, Dimitrios Cannon, Christopher P Pun, Patrick H Corbalan Herreros, Ramon Luis Leiter, Lawrence A Cherney, David Z I Scirica, Benjamin M Kristensen, Steen Dalby García-Castillo, Armando Roussel, Ronan Bonora, Enzo Wang, Sophie Lopes, Renato D Lee, Richard H Scott, Russell Scialla, Julia |
| Contributor_xml | – sequence: 1 givenname: Deepak L surname: Bhatt fullname: Bhatt, Deepak L – sequence: 2 givenname: Christopher P surname: Cannon fullname: Cannon, Christopher P – sequence: 3 givenname: Lawrence A surname: Leiter fullname: Leiter, Lawrence A – sequence: 4 givenname: Julia B surname: Lewis fullname: Lewis, Julia B – sequence: 5 givenname: Darren K surname: McGuire fullname: McGuire, Darren K – sequence: 6 givenname: MHScBertram surname: Pitt fullname: Pitt, MHScBertram – sequence: 7 givenname: Matthew C surname: Riddle fullname: Riddle, Matthew C – sequence: 8 givenname: Gabriel surname: Steg fullname: Steg, Gabriel – sequence: 9 givenname: Hertzel C surname: Gerstein fullname: Gerstein, Hertzel C – sequence: 10 givenname: Gary S surname: Francis fullname: Francis, Gary S – sequence: 11 givenname: John E surname: Gerich fullname: Gerich, John E – sequence: 12 givenname: Johannes F E surname: Mann fullname: Mann, Johannes F E – sequence: 13 givenname: Weichung Joe surname: Shih fullname: Shih, Weichung Joe – sequence: 14 givenname: James B surname: Young fullname: Young, James B – sequence: 15 givenname: Clifford J surname: Bailey fullname: Bailey, Clifford J – sequence: 16 givenname: David Z I surname: Cherney fullname: Cherney, David Z I – sequence: 17 givenname: Jamie P surname: Dwyer fullname: Dwyer, Jamie P – sequence: 18 givenname: Silvio E surname: Inzucchi fullname: Inzucchi, Silvio E – sequence: 19 givenname: Mikhail N surname: Kosiborod fullname: Kosiborod, Mikhail N – sequence: 20 givenname: Benjamin M surname: Scirica fullname: Scirica, Benjamin M – sequence: 21 givenname: Renato D surname: Lopes fullname: Lopes, Renato D – sequence: 22 givenname: Jennifer B surname: Green fullname: Green, Jennifer B – sequence: 23 givenname: Karen P surname: Alexander fullname: Alexander, Karen P – sequence: 24 givenname: Bryan C surname: Batch fullname: Batch, Bryan C – sequence: 25 givenname: W Schuyler surname: Jones fullname: Jones, W Schuyler – sequence: 26 givenname: J Dedrick surname: Jordan fullname: Jordan, J Dedrick – sequence: 27 givenname: Bradley J surname: Kolls fullname: Kolls, Bradley J – sequence: 28 givenname: David F surname: Kong fullname: Kong, David F – sequence: 29 givenname: Wanda C surname: Lakey fullname: Lakey, Wanda C – sequence: 30 givenname: Richard H surname: Lee fullname: Lee, Richard H – sequence: 31 givenname: Robin surname: Mathews fullname: Mathews, Robin – sequence: 32 givenname: Robert W surname: McGarrah fullname: McGarrah, Robert W – sequence: 33 givenname: Rajendra H surname: Mehta fullname: Mehta, Rajendra H – sequence: 34 givenname: Chiara surname: Melloni fullname: Melloni, Chiara – sequence: 35 givenname: John P surname: Middleton fullname: Middleton, John P – sequence: 36 givenname: Thomas J surname: Povsic fullname: Povsic, Thomas J – sequence: 37 givenname: Patrick H surname: Pun fullname: Pun, Patrick H – sequence: 38 givenname: Julia J surname: Scialla fullname: Scialla, Julia J – sequence: 39 givenname: Shreyansh surname: Shah fullname: Shah, Shreyansh – sequence: 40 givenname: Luciano A surname: Sposato fullname: Sposato, Luciano A – sequence: 41 givenname: Thomas J surname: Weber fullname: Weber, Thomas J – sequence: 42 givenname: Casey surname: Norris fullname: Norris, Casey – sequence: 43 givenname: Jill surname: Marcus fullname: Marcus, Jill – sequence: 44 givenname: Nikieia surname: Hayden fullname: Hayden, Nikieia – sequence: 45 givenname: Dimitrios surname: Stournaras fullname: Stournaras, Dimitrios – sequence: 46 givenname: Sophie surname: Wang fullname: Wang, Sophie – sequence: 47 givenname: Linley surname: Brown fullname: Brown, Linley – sequence: 48 givenname: Dominique surname: Larrey fullname: Larrey, Dominique – sequence: 49 givenname: James surname: Lewis fullname: Lewis, James – sequence: 50 givenname: Joshua surname: Beckman fullname: Beckman, Joshua – sequence: 51 givenname: Marc surname: Bonaca fullname: Bonaca, Marc – sequence: 52 givenname: Nicholas surname: Leeper fullname: Leeper, Nicholas – sequence: 53 givenname: Phillip surname: Banks fullname: Banks, Phillip – sequence: 54 givenname: Eshetu surname: Tesfaye fullname: Tesfaye, Eshetu – sequence: 55 givenname: Kenneth surname: Kassler-Taub fullname: Kassler-Taub, Kenneth – sequence: 56 givenname: Chris surname: Warner fullname: Warner, Chris – sequence: 57 givenname: Mark surname: O'Neill fullname: O'Neill, Mark – sequence: 58 givenname: Rosemary surname: Molinari Covance fullname: Molinari Covance, Rosemary – sequence: 59 givenname: Rafael surname: Díaz fullname: Díaz, Rafael – sequence: 60 givenname: Mark surname: Cooper fullname: Cooper, Mark – sequence: 61 givenname: Chantal surname: Mathieu fullname: Mathieu, Chantal – sequence: 62 givenname: Freddy surname: Goldberg Eliaschewitz fullname: Goldberg Eliaschewitz, Freddy – sequence: 63 givenname: Tsvetalina surname: Tankova fullname: Tankova, Tsvetalina – sequence: 64 givenname: Jacob A surname: Udell fullname: Udell, Jacob A – sequence: 65 givenname: Ramon Luis surname: Corbalan Herreros fullname: Corbalan Herreros, Ramon Luis – sequence: 66 givenname: Lixin surname: Jiang fullname: Jiang, Lixin – sequence: 67 givenname: Martin surname: Haluzík fullname: Haluzík, Martin – sequence: 68 givenname: Ales surname: Linhart fullname: Linhart, Ales – sequence: 69 givenname: Steen Dalby surname: Kristensen fullname: Kristensen, Steen Dalby – sequence: 70 givenname: Toomas surname: Marandi fullname: Marandi, Toomas – sequence: 71 givenname: Ronan surname: Roussel fullname: Roussel, Ronan – sequence: 72 givenname: Vakhtang surname: Chumburidze fullname: Chumburidze, Vakhtang – sequence: 73 givenname: Jochen surname: Seufert fullname: Seufert, Jochen – sequence: 74 givenname: Nikolaos surname: Tentolouris fullname: Tentolouris, Nikolaos – sequence: 75 givenname: Milton surname: Rivera fullname: Rivera, Milton – sequence: 76 givenname: Béla Peter surname: Merkely fullname: Merkely, Béla Peter – sequence: 77 givenname: Vijay Kumar surname: Chopra fullname: Chopra, Vijay Kumar – sequence: 78 givenname: Doron surname: Zahger fullname: Zahger, Doron – sequence: 79 givenname: Enzo surname: Bonora fullname: Bonora, Enzo – sequence: 80 givenname: Aivars surname: Lejnieks fullname: Lejnieks, Aivars – sequence: 81 givenname: Birutė surname: Žilaitienė fullname: Žilaitienė, Birutė – sequence: 82 givenname: Tatjana surname: Milenkovic fullname: Milenkovic, Tatjana – sequence: 83 givenname: Armando surname: García-Castillo fullname: García-Castillo, Armando – sequence: 84 givenname: Marcel surname: De Vries fullname: De Vries, Marcel – sequence: 85 givenname: Russell surname: Scott fullname: Scott, Russell – sequence: 86 givenname: Hilde surname: Risstad fullname: Risstad, Hilde – sequence: 87 givenname: Helard Andres surname: Manrique Hurtado fullname: Manrique Hurtado, Helard Andres – sequence: 88 givenname: Roger Martin surname: Correa Flores fullname: Correa Flores, Roger Martin – sequence: 89 givenname: Zbigniew surname: Gaciong fullname: Gaciong, Zbigniew – sequence: 90 givenname: Pedro Filipe surname: Lopes Silva Monteiro fullname: Lopes Silva Monteiro, Pedro Filipe – sequence: 91 givenname: Cristian surname: Guja fullname: Guja, Cristian – sequence: 92 givenname: Nadir M surname: Akhmedzhanov fullname: Akhmedzhanov, Nadir M – sequence: 93 givenname: Neboiša surname: Lalić fullname: Lalić, Neboiša – sequence: 94 givenname: Emil surname: Martinka fullname: Martinka, Emil – sequence: 95 givenname: Jan surname: Murin fullname: Murin, Jan – sequence: 96 givenname: Lesley Jean surname: Burgess fullname: Burgess, Lesley Jean – sequence: 97 givenname: MyungHo surname: Jeong fullname: Jeong, MyungHo – sequence: 98 givenname: José surname: López-Sendón fullname: López-Sendón, José – sequence: 99 givenname: Jonas surname: Oldgren fullname: Oldgren, Jonas – sequence: 100 givenname: Gottfried surname: Rudofsky fullname: Rudofsky, Gottfried |
| Copyright | Copyright © 2020 Massachusetts Medical Society. All rights reserved. Copyright © 2020 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2020 Massachusetts Medical Society. |
| CorporateAuthor | SCORED Investigators |
| CorporateAuthor_xml | – name: SCORED Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1056/NEJMoa2030186 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & allied health premium. Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 139 |
| ExternalDocumentID | 33200891 10_1056_NEJMoa2030186 NJ202101143840208 |
| Genre | Original Article Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | - 0R 0WA 123 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACPVT ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MQT MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM R.3 UIG VXZ YIF YIN Z5M 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c390t-65a898f0ee607ff58f939ec5ec9aaee5d638d73980c6837c27ab9d3979a1ae1b3 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 1111 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000609886200012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Thu Sep 04 15:39:11 EDT 2025 Sat Nov 29 14:32:58 EST 2025 Wed Feb 19 02:28:48 EST 2025 Tue Nov 18 21:59:17 EST 2025 Sat Nov 29 03:02:09 EST 2025 Tue Dec 21 14:38:58 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2020 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c390t-65a898f0ee607ff58f939ec5ec9aaee5d638d73980c6837c27ab9d3979a1ae1b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0003-0508-0954 0000-0001-6896-2941 0000-0003-4596-2791 0000-0002-1278-6245 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa2030186?articleTools=true |
| PMID | 33200891 |
| PQID | 2477703057 |
| PQPubID | 40644 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2461398330 proquest_journals_2477703057 pubmed_primary_33200891 crossref_primary_10_1056_NEJMoa2030186 crossref_citationtrail_10_1056_NEJMoa2030186 mms_nejm_10_1056_NEJMoa2030186 |
| PublicationCentury | 2000 |
| PublicationDate | 20210114 2021-01-14 |
| PublicationDateYYYYMMDD | 2021-01-14 |
| PublicationDate_xml | – month: 01 year: 2021 text: 20210114 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2021 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | McMurray, JJV, Solomon, SD, Inzucchi, SE (r021) 2019; 381 Verma, S, Mazer, CD, Yan, AT (r040) 2019; 140 Wiviott, SD, Raz, I, Bonaca, MP (r014) 2019; 380 Seidelmann, SB, Feofanova, E, Yu, B (r042) 2018; 72 Sherman, SE, Bell, GI, Teoh, H (r036) 2018; 3 Connelly, KA, Bhatt, DL, Verma, S (r010) 2018; 28 Cavender, MA, Steg, PG, Smith, SC (r004) 2015; 132 Bhatt, DL, Verma, S, Braunwald, E (r008) 2019; 30 Zinman, B, Wanner, C, Lachin, JM (r011) 2015; 373 Kumar, N, Garg, A, Bhatt, DL (r035) 2018; 96 Buse, JB, Garg, SK, Rosenstock, J (r028) 2018; 41 Cannon, CP, Pratley, R, Dagogo-Jack, S (r020) 2020; 383 Neal, B, Perkovic, V, Mahaffey, KW (r012) 2017; 377 Sands, AT, Zambrowicz, BP, Rosenstock, J (r026) 2015; 38 Steg, PG, Bhatt, DL, Wilson, PWF (r002) 2007; 297 Bhatt, DL, Steg, PG, Ohman, EM (r003) 2006; 295 Packer, M, Anker, SD, Butler, J (r022) 2020; 383 Scirica, BM, Bhatt, DL, Braunwald, E (r007) 2016; 1 Heerspink, HJL, Stefánsson, BV, Correa-Rotter, R (r019) 2020; 383 Udell, JA, Bhatt, DL, Braunwald, E (r023) 2015; 38 Verma, S, Mazer, CD, Bhatt, DL (r039) 2019; 42 Gaudino, M, Arvind, V, Hameed, I (r044) 2020; 76 Udell, JA, Cavender, MA, Bhatt, DL, Chatterjee, S, Farkouh, ME, Scirica, BM (r006) 2015; 3 Stukel, TA, Glynn, RJ, Fisher, ES, Sharp, SM, Lu-Yao, G, Wennberg, JE (r032) 1994; 13 Verma, S, Bhatt, DL (r009) 2019; 140 Avogaro, A, Fadini, GP, Del Prato, S (r038) 2020; 43 Danne, T, Cariou, B, Banks, P (r029) 2018; 41 Andersen, PK, Angst, J, Ravn, H (r031) 2019; 25 Scirica, BM, Braunwald, E, Raz, I (r015) 2014; 130 Tyl, B, Lopez Sendon, J, Borer, JS (r048) 2020; 13 Garg, SK, Henry, RR, Banks, P (r024) 2017; 377 Packer, M (r037) 2020; 43 Gaba, P, Bhatt, DL (r043) 2020; 17 Patel, T, Tesfaldet, B, Chowdhury, I (r049) 2018; 391 Selvaraj, S, Greene, SJ, Khatana, SAM, Nathan, AS, Solomon, SD, Bhatt, DL (r045) 2020; 9 Chowdhury, B, Luu, AZ, Luu, VZ (r034) 2020; 524 Powell, DR, Zambrowicz, B, Morrow, L (r027) 2020; 105 Bagiella, E, Bhatt, DL, Gaudino, M (r030) 2020; 76 Zelniker, TA, Wiviott, SD, Raz, I (r017) 2019; 393 Vaduganathan, M, Sathiyakumar, V, Singh, A (r018) 2018; 72 Scirica, BM, Bhatt, DL, Braunwald, E (r005) 2013; 369 Hess, DA, Terenzi, DC, Trac, JZ (r033) 2019; 30 Perkovic, V, Jardine, MJ, Neal, B (r013) 2019; 380 Jatene, T, Harrington, RA, Stone, GW (r047) 2016; 67 Rodbard, HW, Giaccari, A, Lajara, R (r025) Opingari, E, Verma, S, Connelly, KA (r041) 2020; 35 Bhatt, DL, Cryer, BL, Contant, CF (r046) 2010; 363 Kato, ET, Silverman, MG, Mosenzon, O (r016) 2019; 139 Bhatt, DL, Eagle, KA, Ohman, EM (r001) 2010; 304 Chowdhury B (e_1_3_5_35_2) 2020; 524 Neal B (e_1_3_5_13_2) 2017; 377 Sherman SE (e_1_3_5_37_2) 2018; 3 Garg SK (e_1_3_5_25_2) 2017; 377 Andersen PK (e_1_3_5_32_2) 2019; 25 Heerspink HJL (e_1_3_5_20_2) 2020; 383 Packer M (e_1_3_5_38_2) 2020; 43 Bhatt DL (e_1_3_5_47_2) 2010; 363 Kumar N (e_1_3_5_36_2) 2018; 96 Verma S (e_1_3_5_40_2) 2019; 42 Hess DA (e_1_3_5_34_2) 2019; 30 Jatene T (e_1_3_5_48_2) 2016; 67 Steg PG (e_1_3_5_3_2) 2007; 297 Cannon CP (e_1_3_5_21_2) 2020; 383 Rodbard HW (e_1_3_5_26_2) 2020 Verma S (e_1_3_5_10_2) 2019; 140 Kato ET (e_1_3_5_17_2) 2019; 139 Scirica BM (e_1_3_5_16_2) 2014; 130 Connelly KA (e_1_3_5_11_2) 2018; 28 Packer M (e_1_3_5_23_2) 2020; 383 Powell DR (e_1_3_5_28_2) 2020; 105 Cavender MA (e_1_3_5_5_2) 2015; 132 Scirica BM (e_1_3_5_6_2) 2013; 369 Buse JB (e_1_3_5_29_2) 2018; 41 Scirica BM (e_1_3_5_8_2) 2016; 1 Gaudino M (e_1_3_5_45_2) 2020; 76 Zelniker TA (e_1_3_5_18_2) 2019; 393 Zinman B (e_1_3_5_12_2) 2015; 373 Avogaro A (e_1_3_5_39_2) 2020; 43 Tyl B (e_1_3_5_49_2) 2020; 13 Bagiella E (e_1_3_5_31_2) 2020; 76 Danne T (e_1_3_5_30_2) 2018; 41 Sands AT (e_1_3_5_27_2) 2015; 38 Udell JA (e_1_3_5_7_2) 2015; 3 Stukel TA (e_1_3_5_33_2) 1994; 13 Wiviott SD (e_1_3_5_15_2) 2019; 380 Opingari E (e_1_3_5_42_2) 2020; 35 Vaduganathan M (e_1_3_5_19_2) 2018; 72 Udell JA (e_1_3_5_24_2) 2015; 38 Bhatt DL (e_1_3_5_2_2) 2010; 304 Bhatt DL (e_1_3_5_4_2) 2006; 295 Selvaraj S (e_1_3_5_46_2) 2020; 9 Perkovic V (e_1_3_5_14_2) 2019; 380 McMurray JJV (e_1_3_5_22_2) 2019; 381 Gaba P (e_1_3_5_44_2) 2020; 17 Bhatt DL (e_1_3_5_9_2) 2019; 30 Verma S (e_1_3_5_41_2) 2019; 140 Patel T (e_1_3_5_50_2) 2018; 391 Seidelmann SB (e_1_3_5_43_2) 2018; 72 33852786 - N Engl J Med. 2021 Apr 15;384(15):1470-1471 33852787 - N Engl J Med. 2021 Apr 15;384(15):1471 33497553 - N Engl J Med. 2021 Jan 14;384(2):179-181 |
| References_xml | – volume: 297 start-page: 1197 year: 2007 end-page: 1206 ident: r002 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis. publication-title: JAMA – volume: 43 start-page: 501 year: 2020 end-page: 507 ident: r038 article-title: Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. publication-title: Diabetes Care – volume: 295 start-page: 180 year: 2006 end-page: 189 ident: r003 article-title: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. publication-title: JAMA – volume: 13 start-page: e006720 issue: 7 year: 2020 end-page: e006720 ident: r048 article-title: Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study. publication-title: Circ Heart Fail – volume: 41 start-page: 1970 year: 2018 end-page: 1980 ident: r028 article-title: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. publication-title: Diabetes Care – volume: 41 start-page: 1981 year: 2018 end-page: 1990 ident: r029 article-title: HbA and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. publication-title: Diabetes Care – volume: 30 start-page: 609 year: 2019 end-page: 613 ident: r033 article-title: SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. publication-title: Cell Metab – volume: 30 start-page: 847 year: 2019 end-page: 849 ident: r008 article-title: The DAPA-HF trial: a momentous victory in the war against heart failure. publication-title: Cell Metab – volume: 383 start-page: 1425 year: 2020 end-page: 1435 ident: r020 article-title: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. publication-title: N Engl J Med – volume: 140 start-page: 1693 year: 2019 end-page: 1702 ident: r040 article-title: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. publication-title: Circulation – volume: 373 start-page: 2117 year: 2015 end-page: 2128 ident: r011 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. publication-title: N Engl J Med – volume: 383 start-page: 1436 year: 2020 end-page: 1446 ident: r019 article-title: Dapagliflozin in patients with chronic kidney disease. publication-title: N Engl J Med – volume: 139 start-page: 2528 year: 2019 end-page: 2536 ident: r016 article-title: Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. publication-title: Circulation – volume: 380 start-page: 347 year: 2019 end-page: 357 ident: r014 article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. publication-title: N Engl J Med – volume: 9 start-page: e018274 issue: 18 year: 2020 end-page: e018274 ident: r045 article-title: The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. publication-title: J Am Heart Assoc – volume: 369 start-page: 1317 year: 2013 end-page: 1326 ident: r005 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. publication-title: N Engl J Med – volume: 13 start-page: 1781 year: 1994 end-page: 1791 ident: r032 article-title: Standardized rates of recurrent outcomes. publication-title: Stat Med – volume: 304 start-page: 1350 year: 2010 end-page: 1357 ident: r001 article-title: Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. publication-title: JAMA – volume: 377 start-page: 2337 year: 2017 end-page: 2348 ident: r024 article-title: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. publication-title: N Engl J Med – volume: 72 start-page: 3370 year: 2018 end-page: 3372 ident: r018 article-title: Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. publication-title: J Am Coll Cardiol – volume: 76 start-page: 342 year: 2020 end-page: 345 ident: r030 article-title: The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. publication-title: J Am Coll Cardiol – volume: 35 start-page: 895 year: 2020 end-page: 897 ident: r041 article-title: The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. publication-title: Nephrol Dial Transplant – volume: 72 start-page: 1763 year: 2018 end-page: 1773 ident: r042 article-title: Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. publication-title: J Am Coll Cardiol – volume: 38 start-page: 696 year: 2015 end-page: 705 ident: r023 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. publication-title: Diabetes Care – volume: 380 start-page: 2295 year: 2019 end-page: 2306 ident: r013 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. publication-title: N Engl J Med – volume: 3 start-page: 356 year: 2015 end-page: 366 ident: r006 article-title: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. publication-title: Lancet Diabetes Endocrinol – volume: 1 start-page: 989 year: 2016 end-page: 998 ident: r007 article-title: Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. publication-title: JAMA Cardiol – volume: 76 start-page: 1605 year: 2020 end-page: 1606 ident: r044 article-title: Effects of the COVID pandemic on active non-COVID clinical trials. publication-title: J Am Coll Cardiol – volume: 391 start-page: 2412 year: 2018 end-page: 2412 ident: r049 article-title: Endpoints in diabetes cardiovascular outcome trials. publication-title: Lancet – volume: 67 start-page: 596 year: 2016 end-page: 598 ident: r047 article-title: Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX Trial. publication-title: J Am Coll Cardiol – volume: 42 start-page: e42 issue: 3 year: 2019 end-page: e44 ident: r039 article-title: Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial. publication-title: Diabetes Care – volume: 393 start-page: 31 year: 2019 end-page: 39 ident: r017 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. publication-title: Lancet – volume: 140 start-page: 1448 year: 2019 end-page: 1450 ident: r009 article-title: More CREDENCE for SGLT2 inhibition. publication-title: Circulation – volume: 363 start-page: 1909 year: 2010 end-page: 1917 ident: r046 article-title: Clopidogrel with or without omeprazole in coronary artery disease. publication-title: N Engl J Med – volume: 130 start-page: 1579 year: 2014 end-page: 1588 ident: r015 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation – ident: r025 article-title: Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. publication-title: Diabetes Obes Metab – volume: 43 start-page: 508 year: 2020 end-page: 511 ident: r037 article-title: SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. publication-title: Diabetes Care – volume: 28 start-page: 813 year: 2018 end-page: 815 ident: r010 article-title: Can we DECLARE a victory against cardio-renal disease in diabetes? publication-title: Cell Metab – volume: 377 start-page: 644 year: 2017 end-page: 657 ident: r012 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes. publication-title: N Engl J Med – volume: 17 start-page: 673 year: 2020 end-page: 675 ident: r043 article-title: The COVID-19 pandemic: a catalyst to improve clinical trials. publication-title: Nat Rev Cardiol – volume: 25 start-page: 681 year: 2019 end-page: 695 ident: r031 article-title: Modeling marginal features in studies of recurrent events in the presence of a terminal event. publication-title: Lifetime Data Anal – volume: 105 start-page: e1235 year: 2020 end-page: e1249 ident: r027 article-title: Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. publication-title: J Clin Endocrinol Metab – volume: 38 start-page: 1181 year: 2015 end-page: 1188 ident: r026 article-title: Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. publication-title: Diabetes Care – volume: 96 start-page: 1184 year: 2018 end-page: 1187 ident: r035 article-title: Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. publication-title: Can J Physiol Pharmacol – volume: 383 start-page: 1413 year: 2020 end-page: 1424 ident: r022 article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure. publication-title: N Engl J Med – volume: 132 start-page: 923 year: 2015 end-page: 931 ident: r004 article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. publication-title: Circulation – volume: 381 start-page: 1995 year: 2019 end-page: 2008 ident: r021 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction. publication-title: N Engl J Med – volume: 524 start-page: 50 year: 2020 end-page: 56 ident: r034 article-title: The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. publication-title: Biochem Biophys Res Commun – volume: 3 start-page: 327 year: 2018 end-page: 329 ident: r036 article-title: Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. publication-title: JACC Basic Transl Sci – volume: 72 start-page: 3370 year: 2018 ident: e_1_3_5_19_2 article-title: Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.08.2202 – volume: 41 start-page: 1970 year: 2018 ident: e_1_3_5_29_2 article-title: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. publication-title: Diabetes Care doi: 10.2337/dc18-0343 – volume: 1 start-page: 989 year: 2016 ident: e_1_3_5_8_2 article-title: Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.3030 – volume: 140 start-page: 1448 year: 2019 ident: e_1_3_5_10_2 article-title: More CREDENCE for SGLT2 inhibition. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.041181 – volume: 3 start-page: 356 year: 2015 ident: e_1_3_5_7_2 article-title: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(15)00044-3 – volume: 41 start-page: 1981 year: 2018 ident: e_1_3_5_30_2 article-title: HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. publication-title: Diabetes Care doi: 10.2337/dc18-0342 – volume: 25 start-page: 681 year: 2019 ident: e_1_3_5_32_2 article-title: Modeling marginal features in studies of recurrent events in the presence of a terminal event. publication-title: Lifetime Data Anal doi: 10.1007/s10985-019-09462-4 – volume: 139 start-page: 2528 year: 2019 ident: e_1_3_5_17_2 article-title: Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.040130 – volume: 132 start-page: 923 year: 2015 ident: e_1_3_5_5_2 article-title: Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.014796 – volume: 96 start-page: 1184 year: 2018 ident: e_1_3_5_36_2 article-title: Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications. publication-title: Can J Physiol Pharmacol doi: 10.1139/cjpp-2018-0359 – volume: 42 start-page: e42 issue: 3 year: 2019 ident: e_1_3_5_40_2 article-title: Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME Trial. publication-title: Diabetes Care doi: 10.2337/dc18-1959 – volume: 524 start-page: 50 year: 2020 ident: e_1_3_5_35_2 article-title: The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2020.01.015 – volume: 76 start-page: 1605 year: 2020 ident: e_1_3_5_45_2 article-title: Effects of the COVID pandemic on active non-COVID clinical trials. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.07.051 – volume: 9 start-page: e018274 issue: 18 year: 2020 ident: e_1_3_5_46_2 article-title: The landscape of cardiovascular clinical trials in the United States initiated before and during COVID-19. publication-title: J Am Heart Assoc doi: 10.1161/JAHA.120.018274 – volume: 130 start-page: 1579 year: 2014 ident: e_1_3_5_16_2 article-title: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.114.010389 – volume: 383 start-page: 1436 year: 2020 ident: e_1_3_5_20_2 article-title: Dapagliflozin in patients with chronic kidney disease. publication-title: N Engl J Med doi: 10.1056/NEJMoa2024816 – volume: 377 start-page: 644 year: 2017 ident: e_1_3_5_13_2 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1611925 – volume: 17 start-page: 673 year: 2020 ident: e_1_3_5_44_2 article-title: The COVID-19 pandemic: a catalyst to improve clinical trials. publication-title: Nat Rev Cardiol doi: 10.1038/s41569-020-00439-7 – volume: 377 start-page: 2337 year: 2017 ident: e_1_3_5_25_2 article-title: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1708337 – volume: 43 start-page: 508 year: 2020 ident: e_1_3_5_38_2 article-title: SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. publication-title: Diabetes Care doi: 10.2337/dci19-0074 – volume: 373 start-page: 2117 year: 2015 ident: e_1_3_5_12_2 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 3 start-page: 327 year: 2018 ident: e_1_3_5_37_2 article-title: Canagliflozin improves the recovery of blood flow in an experimental model of severe limb ischemia. publication-title: JACC Basic Transl Sci doi: 10.1016/j.jacbts.2018.01.010 – volume: 72 start-page: 1763 year: 2018 ident: e_1_3_5_43_2 article-title: Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.07.061 – volume: 304 start-page: 1350 year: 2010 ident: e_1_3_5_2_2 article-title: Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.2010.1322 – year: 2020 ident: e_1_3_5_26_2 article-title: Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. publication-title: Diabetes Obes Metab doi: 10.1111/dom.14127 – volume: 13 start-page: 1781 year: 1994 ident: e_1_3_5_33_2 article-title: Standardized rates of recurrent outcomes. publication-title: Stat Med doi: 10.1002/sim.4780131709 – volume: 381 start-page: 1995 year: 2019 ident: e_1_3_5_22_2 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction. publication-title: N Engl J Med doi: 10.1056/NEJMoa1911303 – volume: 38 start-page: 1181 year: 2015 ident: e_1_3_5_27_2 article-title: Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. publication-title: Diabetes Care doi: 10.2337/dc14-2806 – volume: 383 start-page: 1425 year: 2020 ident: e_1_3_5_21_2 article-title: Cardiovascular outcomes with ertugliflozin in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa2004967 – volume: 43 start-page: 501 year: 2020 ident: e_1_3_5_39_2 article-title: Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. publication-title: Diabetes Care doi: 10.2337/dc19-1410 – volume: 30 start-page: 609 year: 2019 ident: e_1_3_5_34_2 article-title: SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. publication-title: Cell Metab doi: 10.1016/j.cmet.2019.08.015 – volume: 38 start-page: 696 year: 2015 ident: e_1_3_5_24_2 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. publication-title: Diabetes Care doi: 10.2337/dc14-1850 – volume: 140 start-page: 1693 year: 2019 ident: e_1_3_5_41_2 article-title: Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.042375 – volume: 369 start-page: 1317 year: 2013 ident: e_1_3_5_6_2 article-title: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. publication-title: N Engl J Med doi: 10.1056/NEJMoa1307684 – volume: 393 start-page: 31 year: 2019 ident: e_1_3_5_18_2 article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. publication-title: Lancet doi: 10.1016/S0140-6736(18)32590-X – volume: 105 start-page: e1235 year: 2020 ident: e_1_3_5_28_2 article-title: Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption. publication-title: J Clin Endocrinol Metab doi: 10.1210/clinem/dgz258 – volume: 363 start-page: 1909 year: 2010 ident: e_1_3_5_47_2 article-title: Clopidogrel with or without omeprazole in coronary artery disease. publication-title: N Engl J Med doi: 10.1056/NEJMoa1007964 – volume: 297 start-page: 1197 year: 2007 ident: e_1_3_5_3_2 article-title: One-year cardiovascular event rates in outpatients with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.297.11.1197 – volume: 13 start-page: e006720 issue: 7 year: 2020 ident: e_1_3_5_49_2 article-title: Comparison of outcome adjudication by investigators and by a central end point committee in heart failure trials: experience of the SHIFT heart failure study. publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.119.006720 – volume: 28 start-page: 813 year: 2018 ident: e_1_3_5_11_2 article-title: Can we DECLARE a victory against cardio-renal disease in diabetes? publication-title: Cell Metab doi: 10.1016/j.cmet.2018.11.010 – volume: 295 start-page: 180 year: 2006 ident: e_1_3_5_4_2 article-title: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. publication-title: JAMA doi: 10.1001/jama.295.2.180 – volume: 380 start-page: 2295 year: 2019 ident: e_1_3_5_14_2 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. publication-title: N Engl J Med doi: 10.1056/NEJMoa1811744 – volume: 30 start-page: 847 year: 2019 ident: e_1_3_5_9_2 article-title: The DAPA-HF trial: a momentous victory in the war against heart failure. publication-title: Cell Metab doi: 10.1016/j.cmet.2019.10.008 – volume: 67 start-page: 596 year: 2016 ident: e_1_3_5_48_2 article-title: Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX Trial. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.11.027 – volume: 383 start-page: 1413 year: 2020 ident: e_1_3_5_23_2 article-title: Cardiovascular and renal outcomes with empagliflozin in heart failure. publication-title: N Engl J Med doi: 10.1056/NEJMoa2022190 – volume: 76 start-page: 342 year: 2020 ident: e_1_3_5_31_2 article-title: The consequences of the COVID-19 pandemic on non-COVID-19 clinical trials. publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.05.041 – volume: 391 start-page: 2412 year: 2018 ident: e_1_3_5_50_2 article-title: Endpoints in diabetes cardiovascular outcome trials. publication-title: Lancet doi: 10.1016/S0140-6736(18)31184-X – volume: 380 start-page: 347 year: 2019 ident: e_1_3_5_15_2 article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. publication-title: N Engl J Med doi: 10.1056/NEJMoa1812389 – volume: 35 start-page: 895 year: 2020 ident: e_1_3_5_42_2 article-title: The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfz294 – reference: 33852787 - N Engl J Med. 2021 Apr 15;384(15):1471 – reference: 33497553 - N Engl J Med. 2021 Jan 14;384(2):179-181 – reference: 33852786 - N Engl J Med. 2021 Apr 15;384(15):1470-1471 |
| SSID | ssj0000149 |
| Score | 2.7416866 |
| Snippet | In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes,... The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with... BackgroundThe efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with... |
| SourceID | proquest pubmed crossref mms |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 129 |
| SubjectTerms | Adverse events Aged Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - mortality Cerebral infarction Confidence intervals Congestive heart failure Corporate sponsorship Creatinine Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic ketoacidosis Diabetic Ketoacidosis - chemically induced Diarrhea Diarrhea - chemically induced Double-Blind Method Female Glomerular filtration rate Glucose Glycosides - adverse effects Glycosides - therapeutic use Heart attacks Heart failure Hemoglobin Hospitalization Hospitalization - statistics & numerical data Humans Ketoacidosis Kidney diseases Male Middle Aged Mycoses - etiology Myocardial infarction Patients Placebos Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Risk factors Sodium-glucose cotransporter Sodium-Glucose Transporter 1 - antagonists & inhibitors Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Statistical analysis |
| SummonAdditionalLinks | – databaseName: Nursing & allied health premium. dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB50FfHi-1EfSwXxZLBtmqY5iYoiiIv4wltJ84DKbqt2V9Bfb9LNrnpYL0JvGULoTPJN5pvMAOxrKS0saoS1YCjWIUY8UhGKpTD-OcmJonnTbIJ2OunTE7txAbfapVWOzsTmoJaVsDHyoyimtLFOevzyimzXKMuuuhYa0zATWuw29kxvH3-Uj3Lur4sguRqbBvOPbKf5ikf2QmCfUf_ApOler57sbjawc7H43wUvwYJzOP2ToYUsw5QqV2Du2lHqq3B6Z4mpbqG71WdR-ua7GZZarX0bo_Vdykzt81L6rpSuf1XIUn2YsYbdWYOHi_P7s0vkGisggVnQRwnhKUt1oFQSUK1JqhlmShAlGOdKEWk2paSYpYFIzAVWRJTnTFoGkIdchTleh1ZZlWoTfE2Mk8aZJFjEBtoI0wbfQjNBxHSCc-LB4ejXZsJVHbfNL7pZw36TJPulCQ8OxuIvw3IbkwTbRk9ZqZ57kwR2RmrJ3Lass2-deLA3HjYbyrIkvFTVwMoYD4elGAcebAxVP14KxjZdhIVbf0--DfORTX0JQhTGO9Dqvw3ULsyK935Rv7UbG_0CLDTq1A priority: 102 providerName: ProQuest |
| Title | Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2030186 https://www.ncbi.nlm.nih.gov/pubmed/33200891 https://www.proquest.com/docview/2477703057 https://www.proquest.com/docview/2461398330 |
| Volume | 384 |
| WOSCitedRecordID | wos000609886200012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (ProQuest) customDbUrl: eissn: 1533-4406 dateEnd: 20250907 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ba9swFD407Rh7WbtLt_QSXBh7mqltWZb02KYtg5HMpN3Im5F1gYzEGXU62H79dBQltJRQCuZ78bEtJB2fz_rkcwA-Wa0xLNqYWCXi3KYklpnJ4lwrx89pTQ2rfbEJNhzy8ViUW3C6-hemMb9mXsBHj8YV6FV1-FOsDT-XGVJ4XnRgx801gbUaLvoX9_JFBb4bloxCUs1Hlz8IQp3ZrN3ML32cudp9dgv34HWglNHZcg68gS3TvIWXgyCav4Pza5SephM7nf-bNJE7ymUy1TbCVdgobIppI9noKCTLjb5NdGP-unNev3kPP64ub_pf41A6IVZEJIu4oJILbhNjioRZS7kVRBhFjRJSGkO1czvNiOCJKtwnqsqYrIVGjU-m0qQ12YftZt6YjxBZ6miYFJoSlbvgRYV1ESx1N8iELUhNu_Bl1ZeVCnnFsbzFtPL6Ni2qB_3Shc9r89_LhBqbDHtuYCrs7k0GR6sxq4LjtVWWM-ZfYqwLJ-vTzmVQB5GNmd-hjeMwghOSdOHDcqzXTSEEN4SI9OCppx_Cqwy3tyRpnOZHsL24vTPH8EL9WUza2x502Ogn4ph55A55P-3BzvnlsBz1_LR1OEhGHm8Qs4HH7x5LRFb-ByD55Ok |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQEX3o-FUoIEnLCa2HEcHxDiVbXadlWJIu0tdfyQFu0mpdlStT-qv7HjxFnKYbn1gJSbR6Mk83kenvEMwBtnjDeLjjCnJUldwoiilpLUaPTPecmtKNthE2I0ysdjub8CF_1dGF9W2evEVlGbWvsz8k2aCtGiU3w8-kX81CifXe1HaHSwGNqzUwzZmg87X1G-bynd-nbwZZuEqQJEY3w_JxlXucxdbG0WC-d47iSTVnOrpVLWcoOINILJPNYZRm-aClVK49NfKlE2KRnyXYUbqMeFLyETY3GlXVVwt8OJVejpiT7Gpp9sXyvqAxB_bfuKDVydzZrl7m1r5rbu_W8_6D7cDQ519KnbAQ9gxVYP4dZeKBl4BJ-_-8TbdOKm9fmkivDZ71rJNpE_g45CSVATqcpEoVVwNJyYyp7hWpu9egw_ruULnsBaVVf2GUSOoxOqpOFMpyhyLh3a7wQZUOkyVvIBvO9FWejQVd0P95gWbXafZ8Vfkh_AuwX5UddOZBnhBuKiqOzP2TKC9R4GRVA7TfEHAwN4vVhGheGzQKqy9YmnQQ9O5ozFA3jaQW3xKoz5chiZPP8381dwe_tgb7fY3RkNX8Ad6st84oQk6TqszY9P7Eu4qX_PJ83xRrs_Iji8brxdAr2fSRA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BVVceEMXSgkScMLaxI7j-IAQUFZUS1crUaTeguOHtNVuUpotqPw0fh3jxFnKYbn1gJSbR1YSf575xjOeAXjujPFm0RHmtCSpSxhR1FKSGo38nJfcirJtNiEmk_z4WE434Fd_F8anVfY6sVXUptb-jHxIUyFadIqhC2kR0_3Rm9NvxHeQ8pHWvp1GB5GxvfiB7lvz-mAf1_oFpaMPR-8_ktBhgGj09Zck4yqXuYutzWLhHM-dZNJqbrVUylpuEJ1GMJnHOkNPTlOhSml8KEwlyiYlw3k34ZpIOfXpZIfx0aXSVYF6h9OrUN8T-cbQd7mvFfXOiL_Cfckebi4WzXqq25q80a3_-WfdhpuBaEdvu51xBzZsdRe2D0MqwT1499kH5OYzN69_zqoIn2lXYraJ_Nl0FFKFmkhVJgolhKPxzFT2AsfaqNZ9-HIlX_AAtqq6sjsQOY7kVEnDmU7RpHPp0K4nOAGVLmMlH8CrflkLHaqt-6Yf86KN-vOs-AsFA3i5Ej_tyoysE9xDjBSVPVmsE9jtIVEEddQUf_AwgGerYVQkPjqkKlufexlkdjJnLB7Aww52q1dhzKfJyOTRvyd_CtsIs-LTwWT8GG5Qn_0TJyRJd2FreXZun8B1_X05a8722q0SwderhttvQWVR4A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sotagliflozin+in+Patients+with+Diabetes+and+Chronic+Kidney+Disease&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Bhatt%2C+Deepak+L&rft.au=Szarek%2C+Michael&rft.au=Pitt%2C+Bertram&rft.au=Cannon%2C+Christopher+P&rft.date=2021-01-14&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=384&rft.issue=2&rft.spage=129&rft.epage=139&rft_id=info:doi/10.1056%2FNEJMoa2030186&rft.externalDocID=NJ202101143840208 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |